Contact
      Please use this form to send email to PR contact of this press release:
      
      TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
    
      TO: